SSR1-containing PCM: A Potential Drug Target for Cancer (G6745)

Target Name: SSR1

NCBI ID: G6745

SSR1

SSR1-containing PCM: A Potential Drug Target for Cancer

SSR1 (short for short for slow-growing recurrent elastase 1) is a gene that has been identified as a potential drug target or biomarker in the field of cancer. The gene is located on chromosome 18 and is responsible for the production of a protein known as SSR1-containing pericapillary matrix (PCM).

SSR1-containing PCM is a protein that is expressed in various tissues throughout the body, including the skin, hair, nails, and connective tissue. It is also expressed in the liver, spleen, and pancreas, among other organs. The protein is involved in the immune response and has been shown to play a role in the regulation of inflammation and fibrosis.

In cancer, SSR1-containing PCM has been shown to be overexpressed or hypermethylated in various tissues, including tumors. This suggests that it may be a useful biomarker or drug target in cancer treatment.

One potential mechanism by which SSR1-containing PCM could be used as a drug target is by targeting its role in the regulation of inflammation and fibrosis. Many cancer treatments are designed to inhibit the immune response or to stimulate apoptosis (programmed cell death), which can lead to the regression of cancer tumors. By inhibiting the role of SSR1-containing PCM in these processes, cancer treatments may be able to enhance their effectiveness.

Another potential mechanism by which SSR1-containing PCM could be used as a drug target is by targeting its role in the regulation of cell signaling pathways. SSR1-containing PCM has been shown to play a role in the regulation of several signaling pathways, including the TGF-β pathway and the NF-kappa-B pathway. These pathways are involved in the regulation of cell growth, differentiation, and inflammation, and have been implicated in the development and progression of many diseases, including cancer. By targeting SSR1-containing PCM with drugs that can modulate these signaling pathways, cancer treatments may be able to enhance their effectiveness.

In addition to its potential as a drug target or biomarker, SSR1-containing PCM is also a potentially promising therapeutic target for cancer because of its involvement in the regulation of the immune response. Many cancer therapies are designed to disrupt the immune response, which can lead to the regression of cancer tumors. By activating the immune response with drugs that can modulate SSR1-containing PCM, cancer treatments may be able to enhance their effectiveness.

Overall, SSR1-containing PCM is a protein that has been identified as a potential drug target or biomarker in the field of cancer. Its involvement in the regulation of inflammation and fibrosis, as well as its potential role in the regulation of cell signaling pathways, make it an attractive target for cancer treatments. Further research is needed to fully understand its potential as a therapeutic agent and to develop safe and effective drugs that can target SSR1-containing PCM.

Protein Name: Signal Sequence Receptor Subunit 1

Functions: TRAP proteins are part of a complex whose function is to bind calcium to the ER membrane and thereby regulate the retention of ER resident proteins. May be involved in the recycling of the translocation apparatus after completion of the translocation process or may function as a membrane-bound chaperone facilitating folding of translocated proteins

The "SSR1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SSR1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets